Skylife has appointed Mr. Zhu Yifei as Chief Commercial Officer.

"Tianyi is currently in a critical period of transition from clinical to commercialization.in the face of urgent clinical needs, our innovations are accelerating to bring more products to the Chinese market to benefit patients."Mr. Zhu Yifei has extensive experience in practical and management experience in the industry, has accumulated deep roots in multinational companies, local pharmaceutical companies and start-ups, and has made great achievements in strategic implementation and commercialization," said Dr. Yu Jingwu, founder, honorary chairman and director of Tianyi Bio.I believe his participation is an important step in the 'Skylife 2.0' strategic landscape, which will actively promote the company's commercial transformation and accelerate the realization of an integrated international biopharmaceutical company with production and sales capabilities, further benefiting patients." Mr. Zhu Yifei graduated from Zhejiang University School of Medicine and has been working in medicine and biotechnology for more than 20 years.before joining Tianyi Bio, he was Vice President and General Manager of The Sales Group, responsible for the sales company function selling and sales and marketing teams, and successfully led the listing of the country's first bevalozumab biosimilar. Prior to, Mr. Zhu Yifei served as Chief Commercial Officer of Baiji Shenzhou.he has made important contributions to the implementation of the expansion and commercialization strategy of the Baiji Shenzhou commercialization team. Mr.Mr. Zhu Yifei has worked in Xi'an Yangsen for more than 20 years, serving in a number of senior management positions, including national sales director, vice president, etc.during this period, he has been responsible for the construction and management of several business units in Xi'an Yangsen, including cancer, immunotherapy, skin, infection and central nervous system..